Mason Street Advisors, LLC Regenxbio Inc. Transaction History

Mason Street Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$33.61 - $49.95 $375,087 - $557,442	-11,160 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$26.52 - $49.35 $1,193 - $2,220	-45 Reduced 0.4%	11,160 $506,000
Q3 2020 Nov 13, 2020	SELL	$27.01 - $40.26 $18,339 - $27,336	-679 Reduced 5.71%	11,205 $308,000
Q2 2020 Aug 14, 2020	BUY	$27.75 - $43.44 $26,834 - $42,006	967 Added 8.86%	11,884 $438,000
Q4 2019 Feb 19, 2020	BUY	$34.54 - $44.87 $10,154 - $13,191	294 Added 2.77%	10,917 $447,000
Q3 2019 Nov 05, 2019	BUY	$31.84 - $50.88 $11,144 - $17,808	350 Added 3.41%	10,623 $378,000
Q2 2019 Aug 12, 2019	BUY	$42.0 - $59.29 $18,816 - $26,561	448 Added 4.56%	10,273 $528,000
Q1 2019 May 07, 2019	BUY	$40.82 - $62.45 $19,430 - $29,726	476 Added 5.09%	9,825 $563,000
Q4 2018 Feb 13, 2019	BUY	$39.11 - $75.15 $25,186 - $48,396	644 Added 7.4%	9,349 $392,000
Q3 2018 Nov 13, 2018	BUY	$65.0 - $82.15 $62,270 - $78,699	958 Added 12.37%	8,705 $657,000
Q2 2018 Aug 14, 2018	BUY	$27.2 - $74.35 $210,718 - $575,989	7,747 New	7,747 $556,000

196

43M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $313M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Mason Street Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Mason Street Advisors, LLC with notifications on news.